Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

542
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
542
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

82
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.0K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

47
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same author

Impact of kidney function on the metabolome in the general population.

PloS one·2026
Same author

Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Repurposing cardiovascular disease prediction models for cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Improving the diagnostic performance of troponin assays for acute myocardial infarction in renal impairment.

Heart (British Cardiac Society)·2026

関連する実験動画

Updated: Sep 30, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.3K

プロテオミクスとメンデルのランダム化を用いて心不全の治療標的を特定

Albert Henry1,2,3, María Gordillo-Marañón1,2, Chris Finan1,2,4

  • 1Institute of Cardiovascular Science (A.H., M.G.-M., C.F., A.F.S., A.D.H.), University College London, United Kingdom.

Circulation
|March 18, 2022
PubMed
まとめ
この要約は機械生成です。

この研究では,心臓機能不全に関連した44のタンパク質が特定され,そのうち8つが因果関係を示した. アドレノメドゥリンは,HF治療の有望な治療対象として登場しました.

キーワード:
メンデルのランダム化分析薬物標的の予測心不全プロテオミクス

さらに関連する動画

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
10:18

Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice

Published on: February 1, 2022

3.2K

関連する実験動画

Last Updated: Sep 30, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.3K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
10:18

Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice

Published on: February 1, 2022

3.2K

科学分野:

  • 心血管疾患の研究
  • プロテオミックとゲノミクス
  • 薬の発見と開発

背景:

  • 心不全 (HF) は,病気のメカニズムが完全に理解されていない広範な状態です.
  • 遺伝的証拠で病気に関連したタンパク質を特定することで,HFの新たな治療標的を明らかにすることができます.

研究 の 目的:

  • 心血管のタンパク質と心不全の間の観察的および因果関係を調査する.
  • 潜在的HF治療のための薬効性タンパク質の標的を特定する.

主な方法:

  • タンパク質とHFの関連性を評価するために,4つの集団研究 (3019人の参加者,732件のHF事件) のメタ分析.
  • 大量のGWAS (>30,000個) からシスタンパク質の定量的な位置を用いたメンデルのランダム化による因果的効果の決定.
  • マルチバースの感受性分析とクロス特性の分析により 安定性を確保し,メカニズムを探求する.

主要な成果:

  • 90のタンパク質のうち44のタンパク質は,HFの発生リスク (P< 6. 0x10^ - 4) と関連していた.
  • CSF-1,Gal-3,KIM-1 (陽性関連) とADM,CHI3L1,CTSL1,FGF-23,MMP-12 (保護性) がHFと強い因果関係を示した.
  • これらのタンパク質の7つは薬効性があり,ADMとGal-3は既に臨床試験中でした.

結論:

  • 発生したHFに関連した44の循環タンパク質を特定し,8つは因果関係を示した.
  • 薬効性のある7つのタンパク質,特にアドレノメドゥリン (ADM) をHFの有望な治療標的として強調した.
  • 複合的な疾患の標的を優先するために,ゲノムとプロテオミクデータを統合する方法を実証した.